2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 6, 2017

9:00AM-11:00AM: Abstract Number: 1001

Persistence, Discontinuation, and Switching Patterns Among Ankylosing Spondylitis Patients Newly Initiating Biologic Therapy

Epidemiology and Public Health Poster II: Rheumatic Diseases Other than Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1552

Persistency of Tumor Necrosis Factor Inhibitor Therapy in US Patients with Ankylosing Spondylitis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1259

Perspectives of Young People with Juvenile Idiopathic Arthritis, Their Caregivers, and Health Care Providers on Transition to Adult Care: Informing Development of a Transition Toolkit

Patient Outcomes, Preferences, and Attitudes Poster II

9:00AM-11:00AM: Abstract Number: 1752

Pharmacokinetics of Rituximab and Clinical Outcomes in Patients with ANCA-Associated Vasculitis

Vasculitis Poster II: ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1514

Phenotype Differences in HLA-B27 Positive Versus Negative Patients with Ankylosing Spondylitis in a Population That Show Relatively Weaker Association with HLA-B27

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1070

Phenotypic Characterization of Peripheral Basophil Perturbations in the Antiphospholipid Syndrome

Innate Immunity and Rheumatic Disease Poster II

9:00AM-11:00AM: Abstract Number: 1167

Phenotypical Features of Patients with Rheumatologic Manifestations of Common Variable Immunodeficiency

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 1209

Phospholipase A2 Group 5 Is a Potential Therapeutic Target for Osteoarthritis Treatment

Osteoarthritis – Clinical Aspects Poster I: Clinical Trials and Interventions

9:00AM-11:00AM: Abstract Number: 1384

Physician Global Assessments for Disease Activity in Rheumatoid Arthritis Are All over the Map!

Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures

9:00AM-11:00AM: Abstract Number: 1781

Pituitary Disease and Granulomatosis with Polyangiitis: A Collaborative Canadian Case Series and Review of the Literature

Vasculitis Poster II: ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1281

Plasma CXCL4 As a Biomarker in Juvenile Systemic Sclerosis

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster II: Lupus and Related Disorders, Myositis, Scleroderma and Vasculitis

9:00AM-11:00AM: Abstract Number: 1303

Polycystic Ovarian Syndrome in Rheumatic Disease

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-11:00AM: Abstract Number: 1228

Postmenopausal Breast Cancer Patients on Aromatase Inhibitor Therapy and Their Increased Risk of Fragility Fracture

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1213

Prediction Model for the Two-Year Risk of Fracture Among Older US Women

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1654

Predictive Factors According to Type of Infection in Systemic Lupus Erythematosus Patients: Data from a Multi-Ethnic, Multi-National, Latin-American Cohort

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].